-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
GPS491
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/2655502-29-5.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 2655502-29-5 |
| Description | GPS491 (EC50 = 0.47 μM) inhibits the expression of HIV-1 structural protein Gag, changes the accumulation of HIV-1 RNA, reduces the abundance of RNAs encoding the structural proteins, and increases the level of viral RNAs encoding the regulatory proteins. |
Product Information
| Synonyms | 2-(trifluoromethyl)-N-(6-(trifluoromethyl)benzo[d]thiazol-2-yl)thiazole-5-carboxamide |
| IUPAC Name | 2-(trifluoromethyl)-N-[6-(trifluoromethyl)-1,3-benzothiazol-2-yl]-1,3-thiazole-5-carboxamide |
| Molecular Weight | 397.32 |
| Molecular Formula | C13H5F6N3OS2 |
| Canonical SMILES | C1=CC2=C(C=C1C(F)(F)F)SC(=N2)NC(=O)C3=CN=C(S3)C(F)(F)F |
| InChI | InChI=1S/C13H5F6N3OS2/c14-12(15,16)5-1-2-6-7(3-5)25-11(21-6)22-9(23)8-4-20-10(24-8)13(17,18)19/h1-4H,(H,21,22,23) |
| InChIKey | FVQKQPWGUPWCHP-UHFFFAOYSA-N |
| Purity | ≥98% |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -23 C for long term (months to years). |
| Complexity | 517 |
| Exact Mass | 396.97782311 |
| Target | HIV |
| XLogP3-AA | 4.7 |
